Investments Iv, L.P.Pro Que... Net Worth

The estimated Net Worth of Investments Iv, L.P.Pro Que... is at least $148 Milión dollars as of 25 April 2017. Investments Que owns over 54,180 units of Eagle Pharmaceuticals Inc stock worth over $227,370 and over the last 8 years Investments sold EGRX stock worth over $147,419,793.

Investments Que EGRX stock SEC Form 4 insiders trading

Investments has made over 24 trades of the Eagle Pharmaceuticals Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently Investments exercised 54,180 units of EGRX stock worth $1,852,414 on 25 April 2017.

The largest trade Investments's ever made was selling 245,770 units of Eagle Pharmaceuticals Inc stock on 2 November 2016 worth over $17,454,585. On average, Investments trades about 83,409 units every 10 days since 2016. As of 25 April 2017 Investments still owns at least 60,957 units of Eagle Pharmaceuticals Inc stock.

You can see the complete history of Investments Que stock trades at the bottom of the page.

Insiders trading at Eagle Pharmaceuticals Inc

Over the last 11 years, insiders at Eagle Pharmaceuticals Inc have traded over $188,911,314 worth of Eagle Pharmaceuticals Inc stock and bought 1,029,065 units worth $16,655,732 . The most active insiders traders include Executive Capital Lphec Man..., Douglas L Braunstein a Investments Iv, L.P.Pro Que.... On average, Eagle Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $193,721. The most recent stock trade was executed by Scott Tarriff on 1 November 2023, trading 21,619 units of EGRX stock currently worth $299,207.

What does Eagle Pharmaceuticals Inc do?

specialty pharmaceutical company

Complete history of Investments Que stock trades at Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc executives and stock owners

Eagle Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Scott Tarriff,
  Chief Executive Officer, Director
• David Pernock,
  President, Chief Operating Officer
• David M. Pernock,
  Exec. VP of Operations
• Brian Joseph Cahill,
  Chief Financial Officer
• Michael Graves,
  Independent Chairman of the Board
• Steven Ratoff,
  Independent Director
• Robert Glenning,
  Independent Director
• Jennifer Simpson,
  Independent Director
• Richard Edlin,
  Independent Director
• Lisa Wilson,
  IR Contact Officer
• Brian Cahill,
  Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
• Debra M. Hussain,
  Sr. VP & Head of Commercial
• Reiner Nowak,
  Exec.
• Dr. Gaozhong Zhu Ph.D.,
  Sr. VP of Pharmaceutical Devel.
• Dr. Valentin R. Curt M.D.,
  Sr. VP of Clinical Drug Devel.
• John Kimmet,
  Exec. VP of Marketing Oncology & Acute Care
• Michael Shawn Moran,
  Exec. VP, Chief Commercial Officer & Principal Operating Officer
• Daniel O'Connor,
  Exec. VP, Chief Strategy Officer & Head of Corp. Devel.
• Ryan Debski,
  Exec. VP, Gen. Counsel & Chief Compliance Officer
• Steven L. Krill,
  Chief Scientific Officer
• Pete A. Meyers,
  Chief Financial Officer
• David E Riggs,
  Chief Financial Officer
• Investments Iv, L.P.Pro Que...,
  
• Sander A Flaum,
  Director
• Douglas L Braunstein,
  Director
• Executive Capital Lphec Man...,
  
• Alain Schreiber,
  Director
• Jay Moorin,
  Director
• Management Llc Pro Quest In...,
  
• Financial Llc Pro Quest Inv...,
  
• Paul Bruinenberg,
  Chief Medical Officer
• Associates Iv Llc Pro Quest...,
  
• Judith Ng Cashin,
  Chief Medical Officer
• Luciana Borio,
  Director
• Michael Shawn Moran,
  EVP, Chief Commercial Officer